NCT00183742

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

Phase I Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 35 (planned)
• Sponsor: University of Southern California · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere) and liposomal doxorubicin (also called Doxil), when given together and to determine the side effects of this combination. Both Taxotere and Doxil are chemotherapy drugs that can decrease the size of several different tumors. Taxotere is approved by the Food and Drug Administration (FDA) for the treatment of breast and lung cancers, and Doxil is approved for the treatment of ovarian cancer.

Conditions

• Cancer
• Carcinoma

Interventions

Type	Name	Description
DRUG	liposomal doxorubicin and docetaxel

Timeline

• Start date: 2000-12-01
• Primary completion: 2005-10-01
• Completion: 2006-05-01
• First posted: 2005-09-16
• Last updated: 2014-05-22

Locations

1 site across 1 country: United States